- Home
- REGN
as 11-20-2024 4:00pm EST
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | TARRYTOWN |
| Market Cap: | 110.0B | IPO Year: | 1991 |
| Target Price: | $1110.63 | AVG Volume (30 days): | 837.3K |
| Analyst Decision: | Buy | Number of Analysts: | 24 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 40.43 | EPS Growth: | 15.31 |
| 52 Week Low/High: | $736.01 - $1211.20 | Next Earning Date: | 10-31-2024 |
| Revenue: | $13,847,100,000 | Revenue Growth: | 5.72% |
| Revenue Growth (this year): | 10.13% | Revenue Growth (next year): | 4.00% |
Stock Insider Trading Activity of Regeneron Pharmaceuticals Inc. (REGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McCourt Marion | REGN | EVP Commercial | Nov 1 '24 | Sell | $844.61 | 1,000 | $844,610.00 | 12,931 | |
| McCourt Marion | REGN | EVP Commercial | Oct 1 '24 | Sell | $1,054.06 | 1,000 | $1,054,060.00 | 12,931 | |
| RYAN ARTHUR F | REGN | Director | Oct 1 '24 | Sell | $1,049.73 | 100 | $104,878.24 | 17,592 | |
| McCourt Marion | REGN | EVP Commercial | Sep 3 '24 | Sell | $1,178.73 | 1,000 | $1,178,730.00 | 12,931 | |
| RYAN ARTHUR F | REGN | Director | Sep 3 '24 | Sell | $1,179.76 | 100 | $117,868.50 | 17,592 | |
| Fenimore Christopher R. | REGN | SVP Finance & CFO | Aug 28 '24 | Sell | $1,205.76 | 5,680 | $6,846,262.22 | 966 |
Latest Regeneron Pharmaceuticals Inc. News
REGN Breaking Stock News: Dive into REGN Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now
Insider Monkey
2 days ago
Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3
Zacks
3 days ago
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
MT Newswires
3 days ago
Deutsche Bank Cuts Regeneron Pharmaceuticals Price Target to $805 From $900, Maintains Hold Rating
Morningstar Research
3 days ago
Analyst Report: Regeneron Pharmaceuticals, Inc.
Pharmaceutical Technology
6 days ago
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
MT Newswires
6 days ago
Wolfe Initiates Regeneron Pharmaceuticals at Outperform With $1,150 Price Target
MT Newswires
6 days ago
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Application for Skin Disease Treatment
Compare REGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REGN Regeneron Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.